The Technical Analyst
Talis Biomedical [TLIS]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Talis Biomedical Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.66% $9.20
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 16.74 mill |
| EPS: | -34.12 |
| P/E: | -0.270 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 1.819 mill |
| Avg Daily Volume: | 0.0092 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.270 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.270 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.80 - 9.61 ( +/- 4.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-01 | Lukowiak Andrew A | Buy | 30 575 | Stock option (right to buy) |
| 2023-08-01 | Lukowiak Andrew A | Buy | 0 | |
| 2023-07-17 | Markovich Rebecca | Buy | 13 071 | Stock option (right to buy) |
| 2023-06-09 | Baker Bros. Advisors Lp | Buy | 23 685 | Non- Qualified Stock Option (right to buy) |
| 2023-06-09 | Scott Randal W. | Buy | 95 000 | Stock option (right to buy) |
| INSIDER POWER |
|---|
| 80.56 |
| Last 91 transactions |
| Buy: 54 998 856 | Sell: 42 065 023 |
Forecast:
16:00 - $9.20
Live Trading Signals (every 1 min)
Forecast
1: 14:41 - $9.02
Forecast 2: 15:31 - $8.99
Forecast 3: 16:00 - $9.20
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.20 (1.66% ) |
| Volume | 0.0033 mill |
| Avg. Vol. | 0.0092 mill |
| % of Avg. Vol | 36.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TLIS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TLIS
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Latest Press Releases
2023-11-14 08:00:00 - Press Release
Talis Biomedical Announces Exploration Of Strategic Alternatives And Cost Reduction Plan To Preserve Cash
Redwood city, calif., nov. 14, 2023 (globe newswire) -- talis biomedical corporation (nasdaq: tlis), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. while the company has made progress developing the talis one® system, it believes that this is a prudent path forward given current market conditions.
2023-08-10 16:05:00 - Press Release
Talis Biomedical Announces Second Quarter 2023 Financial Results And Business Update
Redwood city, calif., aug. 10, 2023 (globe newswire) -- talis biomedical corporation (nasdaq: tlis), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today reported financial results for the second quarter ended june 30, 2023, and provided a business update.
2023-08-03 08:00:00 - Press Release
Talis Biomedical To Report Second Quarter 2023 Financial Results And Provide A Business Update On August 10, 2023
Redwood city, calif., aug. 03, 2023 (globe newswire) -- talis biomedical corporation (nasdaq: tlis), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on thursday, august 10, 2023, after market close. company management will host a corresponding conference call beginning at 1:30 p.m. pacific time (4:30 p.m. eastern time).
2023-08-02 08:00:00 - Press Release
Talis Biomedical Announces Andrew Lukowiak, Ph.d., As President And Chief Scientific Officer (cso)
Redwood city, calif., aug. 02, 2023 (globe newswire) -- talis biomedical corporation (nasdaq: tlis), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care (poc), today announced that it has appointed dr. andrew a. lukowiak as president and chief scientific officer, effective august 1, 2023.
2023-07-24 08:00:00 - Press Release
Talis Biomedical Regains Compliance With Nasdaq Minimum Bid Price Requirement
Redwood city, calif., july 24, 2023 (globe newswire) -- talis biomedical corporation (nasdaq: tlis), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it received written notice (the “notice”) from the nasdaq stock market llc (“nasdaq”) dated july 20, 2023, that the company has regained compliance with the minimum bid price requirement of at least $1.00 per share under nasdaq listing rule 5550(a)(2) (the “minimum bid price requirement”). in order to regain compliance, the company's common stock was required to maintain a closing bid price of at least $1...
Latest News
2023-08-10 21:02:12 - InvestorPlace
7 Small-Cap Stocks to Sell in August Before They Crash and Burn
Although speculative enterprises tend to draw in a loyal band of followers, certain circumstances call for decisive action, as these small-cap stocks to avoid in August confirms. Nobody wants to be the guy or gal throwing in the towel.
2023-08-03 08:00:00 - GlobeNewsWire
Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
2023-05-14 10:58:02 - Seeking Alpha
Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Becky Markovich - Interim Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.
2023-05-04 08:00:00 - GlobeNewsWire
Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023
REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will provide a business update and financial results on Thursday, May 11, 2023, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
2022-08-05 15:48:04 - Seeking Alpha
Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q2 2022 Results - Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants Emily Faucette - Senior Vice President, Corporate Communications & Investor Relations Rob Kelley - Chief Executive Officer Roger Moody - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Mike Ryskin - Bank of America Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the Talis Biomedical's Business Update Conference Call.
2022-05-15 11:08:04 - Seeking Alpha
Talis Biomedical Corporation(TLIS) CEO Rob Kelly on Q12022 Results - Earnings Call Transcript
Talis Biomedical Corporation (NASDAQ:TLIS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Emily Faucette - SVP-Corporate Communications and IR Rob Kelley - CEO Roger Moody - CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Mark Massaro - BTIG Operator Thank you all for standing by, and welcome to Talis's First Quarter 2022 Earnings Conference Call. [Operator Instructions] I'll now turn the call over to your host, Emily Faucette.
2022-04-26 08:00:00 - GlobeNewsWire
Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022
MENLO PARK, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation ("TLIS"), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report first quarter financial results on Tuesday, May 10, 2022, after market close. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
2022-04-25 12:08:35 - Market Watch
Talis Biomedical stock bounces off record low after largest shareholder pulls share-sale plans
Shares of Talis Biomedical Corp. TLIS, +2.34% bounced 1.9% in midday trading Monday, after the diagnostic testing company requested a withdrawal of a large share offering by a selling shareholder. After the March 15 closing bell, the company had registered 37.49 million common shares for sale, including 7.63 million common shares and 29.86 million shares issuable after the conversion of convertible preferred stock, by entities affiliated with Baker Bros.
2022-03-15 22:09:04 - Seeking Alpha
Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q4 2021 Results - Earnings Call Transcript
Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q4 2021 Results - Earnings Call Transcript
2021-11-15 21:40:02 - Seeking Alpha
Talis Biomedical Corporation (TLIS) CEO Kim Popovits on Q3 2021 Results - Earnings Call Transcript
Talis Biomedical Corporation (TLIS) CEO Kim Popovits on Q3 2021 Results - Earnings Call Transcript